Sesen Bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SESN research report →
Companysesenbio.com
Sesen Bio, Inc. , a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors.
- CEO
- Thomas R. Cannell D.V.M.
- IPO
- 2014
- Employees
- 17
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $127.96M
- P/E
- 0.84
- P/S
- -12.04
- P/B
- -30.31
- EV/EBITDA
- 2.57
- Div Yield
- 57.25%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -1048.06%
- Net Margin
- -292.77%
- ROE
- -111.70%
- ROIC
- -105436.38%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-60,477,000 · 0.00%
- EPS
- $-1.46 · 0.00%
- Op Income
- $0
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.96
- 52W Low
- $0.36
- 50D MA
- $0.60
- 200D MA
- $0.62
- Beta
- 0.83
- Avg Volume
- 1.24M
Get TickerSpark's AI analysis on SESN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 6, 23 | Kelly Steven | other | 600,000 |
| Jun 6, 23 | ZWEIFACH SANFORD S | other | 38,700 |
| Jun 6, 23 | Morris Richard Steven | other | 238,000 |
| Jun 6, 23 | Torok Michael | other | 38,700 |
| Jun 6, 23 | Klichinsky Michael | other | 238,000 |
| Jun 6, 23 | Ugwumba Chidozie | other | 38,700 |
| Jun 6, 23 | Morrison Briggs | other | 38,700 |
| Mar 7, 23 | ModernaTX, Inc. | other | 0 |
| Mar 7, 23 | Kelly Steven | other | 625,797 |
| Mar 7, 23 | Kelly Steven | other | 415,968 |
Our SESN Coverage
We haven't published any research on SESN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SESN Report →